BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
Animals
Antibodies, Monoclonal
/ therapeutic use
Antigens, CD
/ genetics
Butyrophilins
/ antagonists & inhibitors
Female
Humans
Immunotherapy
/ methods
Intraepithelial Lymphocytes
/ immunology
Mice
Mice, Transgenic
Ovarian Neoplasms
/ immunology
Receptors, Antigen, T-Cell, alpha-beta
/ immunology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
21 08 2020
21 08 2020
Historique:
received:
12
06
2019
revised:
11
05
2020
accepted:
30
06
2020
entrez:
22
8
2020
pubmed:
21
8
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
Gamma delta (γδ) T cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ major histocompatibility complex-independent tumoricidal potential. Activation of γδ T cells can be elicited by butyrophilin and butyrophilin-like molecules that are structurally similar to the immunosuppressive B7 family members, yet how they regulate and coordinate αβ and γδ T cell responses remains unknown. Here, we report that the butyrophilin BTN3A1 inhibits tumor-reactive αβ T cell receptor activation by preventing segregation of N-glycosylated CD45 from the immune synapse. Notably, CD277-specific antibodies elicit coordinated restoration of αβ T cell effector activity and BTN2A1-dependent γδ lymphocyte cytotoxicity against BTN3A1
Identifiants
pubmed: 32820120
pii: 369/6506/942
doi: 10.1126/science.aay2767
pmc: PMC7646930
mid: NIHMS1609926
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antigens, CD
0
BTN3A1 protein, human
0
Butyrophilins
0
Receptors, Antigen, T-Cell, alpha-beta
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
942-949Subventions
Organisme : NCI NIH HHS
ID : U01 CA232758
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA010815
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009140
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211913
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA240434
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157664
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS114653
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178687
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA248106
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA124515
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184185
Pays : United States
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
J Exp Med. 2016 Feb 8;213(2):177-87
pubmed: 26809444
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7311-E7320
pubmed: 28807997
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Clin Exp Immunol. 2010 Aug;161(2):290-7
pubmed: 20491785
Annu Rev Immunol. 2016 May 20;34:151-72
pubmed: 26772212
J Biol Chem. 2012 Sep 21;287(39):32780-90
pubmed: 22846996
Curr Opin Biotechnol. 2014 Dec;30:128-39
pubmed: 25035939
Science. 2020 Feb 7;367(6478):
pubmed: 31919129
Cell Rep. 2016 Feb 23;14(7):1774-1786
pubmed: 26876172
Front Immunol. 2018 Jul 11;9:1601
pubmed: 30050536
Immunity. 2020 Mar 17;52(3):487-498.e6
pubmed: 32155411
Nat Immunol. 2013 Sep;14(9):908-16
pubmed: 23872678
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1039-1044
pubmed: 29339503
Cancer Cell. 2015 Jan 12;27(1):27-40
pubmed: 25533336
J Immunol. 2013 Aug 1;191(3):1029-42
pubmed: 23833237
J Immunol. 2007 Feb 1;178(3):1523-33
pubmed: 17237401
Science. 1998 Jan 2;279(5347):88-91
pubmed: 9417031
Immunol Cell Biol. 2008 Oct;86(7):608-15
pubmed: 18607388
Oncotarget. 2010 Sep;1(5):329-38
pubmed: 21113407
Cell. 2016 Sep 22;167(1):203-218.e17
pubmed: 27641500
Immunity. 2014 Apr 17;40(4):490-500
pubmed: 24703779
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Nat Commun. 2018 Feb 21;9(1):732
pubmed: 29467364
Science. 1993 Apr 23;260(5107):544-6
pubmed: 8475387
Immunity. 2017 Jan 17;46(1):51-64
pubmed: 28099864
Trends Immunol. 2012 Jan;33(1):34-41
pubmed: 22030238
Eur J Immunol. 2011 Dec;41(12):3443-54
pubmed: 21918970
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Nature. 2001 Jan 18;409(6818):349-54
pubmed: 11201744
Immunity. 2019 Apr 16;50(4):1043-1053.e5
pubmed: 30902636
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Trends Cancer. 2017 Aug;3(8):561-570
pubmed: 28780933
Blood. 2012 Sep 13;120(11):2269-79
pubmed: 22767497
J Immunol. 2010 Nov 15;185(10):5907-14
pubmed: 20944003
Nat Immunol. 2016 May;17(5):574-582
pubmed: 26998761
Nat Biotechnol. 2002 Feb;20(2):143-8
pubmed: 11821859